AbbVie
ABBV
2,226 hedge funds and large institutions have $82.7B invested in AbbVie in 2020 Q1 according to their latest regulatory filings, with 148 funds opening new positions, 1,009 increasing their positions, 839 reducing their positions, and 135 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 113 → 150 (+37)
20% more repeat investments, than reductions
Existing positions increased: 1,009 | Existing positions reduced: 839
1.32% more ownership
Funds ownership: 72.42% → 73.75% (+1.3%)
10% more first-time investments, than exits
New positions opened: 148 | Existing positions closed: 135
1% less funds holding
Funds holding: 2,244 → 2,226 (-18)
13% less capital invested
Capital invested by funds: $94.8B → $82.7B (-$12.1B)
20% less call options, than puts
Call options by funds: $1.4B | Put options by funds: $1.75B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.26B |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$444M |
| 3 |
JP Morgan Chase
New York
|
+$382M |
| 4 |
Bank of New York Mellon
New York
|
+$296M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$258M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$3.18B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$446M |
| 3 |
Two Sigma Advisers
New York
|
-$265M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$248M |
| 5 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$218M |
ABBV Hedge Fund Activity: Q1 2020 in Review
2,226 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2020, worth a combined $82.7B — down 13% from $94.8B a quarter earlier.
Buyers outnumbered sellers: 148 funds opened new ABBV positions and 135 closed out — a net gain of 13 holders — while 1,009 added to existing stakes and 839 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $1.26B. The largest seller was Capital Research Global Investors, cutting an estimated $3.18B.
- 2,226 institutional investors held AbbVie (ABBV) as of Q1 2020, down from 2,244 in Q4 2019.
- Funds reported $82.7B of AbbVie stock for Q1 2020, down 13% quarter-over-quarter.
- 148 funds opened new AbbVie positions in Q1 2020 and 135 closed out, a net change of +13 holders.
- The largest AbbVie buyer in Q1 2020 was T. Rowe Price Associates, an estimated $1.26B added.
- The largest AbbVie seller in Q1 2020 was Capital Research Global Investors, an estimated $3.18B sold.
Based on aggregated 13F filings for Q1 2020.